These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7144688)

  • 21. [Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].
    Riesco J; Troncoso G; Costamaillere L; Rodríguez J
    Rev Med Chil; 1977 Jun; 105(6):375-9. PubMed ID: 331428
    [No Abstract]   [Full Text] [Related]  

  • 22. [Mazindol in the treatment of simple obesity].
    Siciński A; Stasiakowa L
    Pol Arch Med Wewn; 1976 Jun; 55(6):581-7. PubMed ID: 781631
    [No Abstract]   [Full Text] [Related]  

  • 23. [Use of mazindol in the dietetic treatment of obesity in patients with essential hypertension].
    Kocemba J; Kawecka-Jaszcz K
    Pol Arch Med Wewn; 1978 Dec; 60(6):517-23. PubMed ID: 366579
    [No Abstract]   [Full Text] [Related]  

  • 24. [Mazindol in the treatment of obesity in diabetics (author's transl)].
    Felt V; Nedvídková J
    Cas Lek Cesk; 1977 Sep; 116(39):1214-7. PubMed ID: 922789
    [No Abstract]   [Full Text] [Related]  

  • 25. [Results in the treatment of obesity by Mazindol (AN 448 Sandoz) in hospitalized subjects using the method of double-blind trial (author's transl)].
    Kreze A; Velemínsky J; Toman A
    Bratisl Lek Listy; 1976 May; 65(5):537-43. PubMed ID: 788862
    [No Abstract]   [Full Text] [Related]  

  • 26. [Evaluation of the effect of mazindol on the motor function of the stomach in obese persons].
    Kucio C; Jonderko K; Skrzypek D
    Pol Arch Med Wewn; 1988 Apr; 79(4):195-9. PubMed ID: 3270813
    [No Abstract]   [Full Text] [Related]  

  • 27. Double-blind evaluation of mazindol in refractory obesity.
    Smith RG; Innes JA; Munro JF
    Br Med J; 1975 Aug; 3(5978):284. PubMed ID: 1097046
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of simple obesity with mazindol under sanatorium conditions].
    Hasik J; Gawlak E; Tycowa M
    Pol Tyg Lek; 1980 Nov; 35(45):1729-31. PubMed ID: 7012806
    [No Abstract]   [Full Text] [Related]  

  • 29. [Evaluation of the effect of mazindol on the metabolism and lipolysis in obese women].
    Kucio C; Zahorska-Markiewicz B; Piskorska D; Semenowicz-Siuda K; Waluga M
    Pol Arch Med Wewn; 1987 Mar; 77(3):73-6. PubMed ID: 3275392
    [No Abstract]   [Full Text] [Related]  

  • 30. [Mazindol in the treatment of obese diabetic patients].
    Dolecek R; Reil P; Skarpová O; Závada M
    Vnitr Lek; 1976 Aug; 22(8):798-804. PubMed ID: 788327
    [No Abstract]   [Full Text] [Related]  

  • 31. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

  • 32. Double-blind trial of mazindol in overweight patients.
    Heber KR
    Med J Aust; 1975 Oct; 2(14):566-7. PubMed ID: 1105106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical trial with a nonamphetaminic anoretic].
    Campagnoli M
    Rev Iber Endocrinol; 1976; 23(137):463-83. PubMed ID: 794978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)].
    Gołebiowska M; Chlebna-Sokoł D; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(2):311-4. PubMed ID: 7017826
    [No Abstract]   [Full Text] [Related]  

  • 35. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
    Bandisode MS; Boshell BR
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of teronak for the treatment of obesity with and without diabetes mellitus].
    Egart FM; Korotkova VD
    Probl Endokrinol (Mosk); 1980; 26(2):16-20. PubMed ID: 7375451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mazindol: its efficacy and mode of action in generating weight loss.
    Johnson WG; Hughes JR
    Addict Behav; 1979; 4(3):237-44. PubMed ID: 495247
    [No Abstract]   [Full Text] [Related]  

  • 38. [Analysis and biotransformation of mazindol (Teronac) a new anti-obesity drug].
    Ebel S; Schütz H
    Arch Kriminol; 1977; 160(3-4):78-86. PubMed ID: 931504
    [No Abstract]   [Full Text] [Related]  

  • 39. A multi-centre trial of mazindol ('Teronac') in general practice in Ireland.
    Evans ER; Wallace MG
    Curr Med Res Opin; 1975; 3(3):132-7. PubMed ID: 1149481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letter: Drugs in obesity.
    Jackson WP; Vinik AI
    S Afr Med J; 1975 May; 49(20):803. PubMed ID: 1098170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.